<sup>18</sup>F-氟脱氧葡萄糖PET在体检中的应用价值研究

杨忠毅; 管樑; 杨忠毅; 管樑

[1]

American Cancer Society. Cancer facts and figures 2000. Atlanta:American Cancer Society. 2000.1-2.

[2]

Michiru Ide, Yutaka Suzuki. Is whole-body FDG-PET valuable for health screening?. Eur J Nucl Med Mol Imaging, 2005, 32(3):339-341.

[3]

Ide M. Cancer screening with FDG-PET. Q J Nucl Med Mol Imaging, 2006, 50(1):23-27.

[4]

Israel O, Yefremov N. Bar-Shalom R, et al. PET/CT detection of unexpected gastrointestinal loci of ¹⁸F-FDG uptake:incidence, localization patterns, and clinical Significance. J Nucl Med, 2005, 46(5):758-762.

[5]

Yasuda S, Ide M. PET and cancer screening. Ann Nucl Med, 2005, 19(3):167-177.

[6]

Chen YK, Ding HJ, Su CT, et al. Application of PET and PET/CT imaging for cancer screening. Anticancer Res,2004, 24(6):4103-4108.

[7]

Yasuda S, lde M, Fujii H, et al. Application of positron emission tomography imaging to cancer screening. Br J Cancer, 2000, 83(12):1607-1611.

[8]

Hustinx R, Benard F, Alavi A. Whole-body PET imaging in the management of patients with cancer. Semin Nuel Med, 2002, 32(1):35-46.

[9]

Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology, 2004, 231(2):305-332.

[10]

Chen YK, Ding HJ, Chen KT, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by ¹⁸F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res, 2005, 25(2B):1421-1426.

[11]

Fischer BM, Mortensen J. The future in diagnosis and staging of lung cancer. Respiration, 2006, 73(3):267-276.

[12]

Borrego Dorado I, Vazquez Albertino R. A proposal for the rational use of the PET in oncology. Rev Esp Med Nucl, 2002, 21(3):163-173.

[13]

Chen YK, Kao CH, Liao AC, et al. Colorectal cancer screening in asymptomatic adults. Anticancer Res, 2003, 23(5b):4357-4361.

[14]

Byrne AM, Hill AD, Skehan S J, et al. Positron emission tomography in the staging and management of breast cancer. Br J Surg, 2004, 91(11):1398-1409.

[15]

Higashi T, Saga T, Nakamoto Y, et al. Diagnosis of paucreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) usefulness and limitations in "clinical reality". Ann Nucl Med, 2003, 17(4):261-279.

[16]

Meignan M, Haioun C, hti E, et al. Value of[¹⁸F]fluorodeoxyglucosepositron emission tomography in managing patients with aggres-sive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma,2006, 6(4):306-313.

[17]

Tamara L, Velez I, Tamara C. Positron emission tomography:a promising diagnostic modality for head and neck pathology. J Oral Maxillofac Surg, 2006, 64(8):1272-1277.

[18]

于长海,汪涛,孙玉鹗,等.肺部良性结节性病变¹⁸F-脱氧葡萄糖正电子发射体层摄影术检查.中华外科杂志,2006,44(2):90-92.

[19]

汪涛,初向阳,孙玉鹗,等.¹⁸F-脱氧葡萄糖正电子发射体层显像检查在肺结核患者中的应用.中国胸心血管外科临床杂志,2006,13(2):73-76.

[20]

Chang JM, Lee H J, Goo JM, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol, 2006, 7(1):57-69.

[21]

Kalvin B, Fekeshazy A, Lengyel Z, et al. Cost-effective PET investigations in oncology. Magy Onkol, 2002, 46(3):203-223.

[22]

Sloka JS, Hollett PD, Mathews, M. Cost effectiveness of positron emission tomography in canada. Med Scl Monit, 2005, 7(5):351-360.

[23]

Gugiani A, Grimaldi A, Rossetti C, Economic analyses on the use of positron emission tomograptly for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy. Q J Nucl Med Mol Imaging, 2004, 48(1):49-61.

[24]

顾爱春,黄钢.PET在肿瘤方面应用的成本效益分析.国际放射医学核医学杂志,2006,30(2):65-68.

[25]

李彪,廖日强.FDG-PET在非小细胞肺癌分期中的成本效益分析.循证医学,2005,5(3):140-142.

[26]

Weckesser M, Schober O. Is whole-body FDG-PET valuable for health screehing?. Against Eur J Nucl Mol Imaging, 2005, 32(3):342-343.